Srinjoy Chakraborti

Srinjoy Chakraborti, PhD, is a highly experienced scientist specializing in antibody and T-cell receptor (TCR) engineering. Currently serving as a Senior Scientist in Antibody Engineering at Marengo Therapeutics since July 2024, Chakraborti previously held positions as Principal Scientist in TCR Engineering at Alloy Therapeutics, Inc. and Scientist in Antibody Engineering at Scholar Rock. As a Damon Runyon Sohn Pediatric Cancer Research Fellow at Albert Einstein College of Medicine, Chakraborti focused on TCR cross-reactivity and antibody discovery. Academic training includes a PhD in Biological and Biomedical Sciences from UMass Chan Medical School, and a Master’s in Medical Microbiology from Kasturba Medical College. An extensive background in clinical microbiology and research complements a strong foundation in medical education and training.